Fabio Efficace

12.0k total citations · 1 hit paper
215 papers, 6.6k citations indexed

About

Fabio Efficace is a scholar working on Oncology, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Fabio Efficace has authored 215 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Oncology, 63 papers in Hematology and 52 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Fabio Efficace's work include Cancer survivorship and care (56 papers), Health Systems, Economic Evaluations, Quality of Life (43 papers) and Childhood Cancer Survivors' Quality of Life (37 papers). Fabio Efficace is often cited by papers focused on Cancer survivorship and care (56 papers), Health Systems, Economic Evaluations, Quality of Life (43 papers) and Childhood Cancer Survivors' Quality of Life (37 papers). Fabio Efficace collaborates with scholars based in Italy, United Kingdom and Netherlands. Fabio Efficace's co-authors include Andrew Bottomley, Carolyn Gotay, Corneel Coens, Crissy T. Kawamoto, Neil K. Aaronson, Francesco Cottone, Jane Blazeby, Marco Vignetti, Franco Mandelli and Giovanni Caocci and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Fabio Efficace

208 papers receiving 6.5k citations

Hit Papers

The Prognostic Significance of Patient-Reported Outcomes ... 2008 2026 2014 2020 2008 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials
    2008 483 citations Andrew Bottomley, Fabio Efficace et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fabio Efficace Italy 46 3.1k 1.5k 1.3k 1.0k 975 215 6.6k
Heidi D. Klepin United States 39 2.9k 0.9× 1.3k 0.9× 1.6k 1.2× 554 0.5× 1.3k 1.4× 227 7.4k
Allison M. Deal United States 53 4.8k 1.5× 2.2k 1.5× 1.9k 1.4× 1.5k 1.5× 486 0.5× 403 10.7k
Lodovico Balducci United States 59 5.8k 1.9× 2.9k 2.0× 1.5k 1.1× 978 1.0× 1.2k 1.2× 283 11.8k
Joseph M. Unger United States 51 5.4k 1.7× 1.9k 1.3× 2.2k 1.6× 513 0.5× 428 0.4× 262 11.1k
Corneel Coens Belgium 47 3.7k 1.2× 2.6k 1.8× 854 0.6× 686 0.7× 431 0.4× 143 9.0k
Martine Extermann United States 48 5.4k 1.7× 2.7k 1.8× 1.8k 1.3× 537 0.5× 664 0.7× 184 11.6k
Floortje Mols Netherlands 52 5.5k 1.8× 1.4k 0.9× 1.1k 0.8× 1.7k 1.7× 463 0.5× 211 8.8k
S B Yellen United States 8 4.3k 1.4× 1.6k 1.1× 1.3k 0.9× 1.9k 1.9× 375 0.4× 9 6.9k
Theresa H.M. Keegan United States 57 4.7k 1.5× 1.2k 0.8× 2.6k 2.0× 3.4k 3.3× 523 0.5× 295 10.9k
Shabbir M.H. Alibhai Canada 55 3.9k 1.3× 4.2k 2.9× 1.4k 1.1× 1.0k 1.0× 566 0.6× 437 11.4k

Countries citing papers authored by Fabio Efficace

Since Specialization
Citations

This map shows the geographic impact of Fabio Efficace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabio Efficace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabio Efficace more than expected).

Fields of papers citing papers by Fabio Efficace

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabio Efficace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabio Efficace. The network helps show where Fabio Efficace may publish in the future.

Co-authorship network of co-authors of Fabio Efficace

This figure shows the co-authorship network connecting the top 25 collaborators of Fabio Efficace. A scholar is included among the top collaborators of Fabio Efficace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabio Efficace. Fabio Efficace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roets, Evelyne, Winette van der Graaf, Rick L. Haas, et al.. (2024). Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review. Critical Reviews in Oncology/Hematology. 197. 104345–104345. 5 indexed citations
2.
Bandieri, Elena, Sarah Bigi, Eleonora Borelli, et al.. (2024). Early palliative care perceptions by patients with cancer and primary caregivers: metaphorical language. BMJ Supportive & Palliative Care. 14(e3). e3011–e3018. 1 indexed citations
3.
Bandieri, Elena, Eleonora Borelli, Sarah Bigi, et al.. (2023). Stigma of Palliative Care among Patients with Advanced Cancer and Their Caregivers on Early Palliative Care. Cancers. 15(14). 3656–3656. 13 indexed citations
4.
Efficace, Fabio, David Cella, Neil K. Aaronson, et al.. (2021). Impact of Blinding on Patient-Reported Outcome Differences Between Treatment Arms in Cancer Randomized Controlled Trials. JNCI Journal of the National Cancer Institute. 114(3). 471–474. 20 indexed citations
5.
Efficace, Fabio, Massimo Breccia, Paola Fazi, et al.. (2021). The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study. JMIR Research Protocols. 10(6). e25271–e25271. 3 indexed citations
6.
Gamper, Eva‐Maria, Francesco Cottone, Kathrin Sommer, et al.. (2021). The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. Journal of Clinical Epidemiology. 137. 31–44. 20 indexed citations
7.
Sommer, Kathrin, Marco Vignetti, Francesco Cottone, et al.. (2020). Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden. BMJ Supportive & Palliative Care. 12(2). 182–186. 2 indexed citations
8.
Peipert, John Devin, Sherif M. Badawy, Sharon H. Baik, et al.. (2020). <p>Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Medication Adherence Scale (PMAS)</p>. Patient Preference and Adherence. Volume 14. 971–983. 13 indexed citations
9.
Cottone, Francesco, Gary S. Collins, Amélie Anota, et al.. (2020). Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies. Journal of Clinical Epidemiology. 127. 9–18. 9 indexed citations
10.
Giesinger, Johannes M., Fanny L. Loth, Neil K. Aaronson, et al.. (2019). Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. Journal of Clinical Epidemiology. 118. 1–8. 198 indexed citations
11.
Retzer, Ameeta, Thomas Keeley, Khaled Ahmed, et al.. (2018). Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol. BMJ Open. 8(2). e017282–e017282. 7 indexed citations
12.
Ahmed, Khaled, Derek Kyte, Thomas Keeley, et al.. (2016). Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol. BMJ Open. 6(9). e012863–e012863. 16 indexed citations
13.
Sodergren, Samantha C., Ellen Copson, Fabio Efficace, et al.. (2015). Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group. Targeted Oncology. 11(3). 277–292. 30 indexed citations
14.
Efficace, Fabio, Gianantonio Rosti, Massimo Breccia, et al.. (2015). The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. Annals of Hematology. 95(2). 211–219. 15 indexed citations
15.
Alonso, Jordi, Susan J. Bartlett, Matthias Rose, et al.. (2013). The case for an international patient-reported outcomes measurement information system (PROMIS®) initiative. Health and Quality of Life Outcomes. 11(1). 210–210. 126 indexed citations
16.
Calvert, Melanie, Michael Brundage, Paul B. Jacobsen, Holger J. Schünemann, & Fabio Efficace. (2013). The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. Health and Quality of Life Outcomes. 11(1). 184–184. 90 indexed citations
17.
Weis, John R., Yan-Li Gao, Thierry Conroy, et al.. (2007). Development of an EORTC module for the assessment of cancer related fatigue (EORTC FAR-15): Phase III results.. UCL Discovery (University College London). 1 indexed citations
18.
19.
Bottomley, Andrew, Egbert F. Smit, Fabio Efficace, et al.. (2005). Non-small cell lung cancer and health-related quality of life (HRQOL): Is baseline HRQOL of prognostic value for survival?. Open Repository and Bibliography (University of Liège). 1 indexed citations
20.
Efficace, Fabio, Andrew Bottomley, & Jane Blazeby. (2003). Randomized clinical trial comparing quality of life after straight and pouch coloanal reconstruction. British journal of surgery. 90(5). 594–595. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heidi D. Klepin Breakdown of academic impact, for papers by Allison M. Deal Breakdown of academic impact, for papers by Lodovico Balducci Breakdown of academic impact, for papers by Joseph M. Unger Breakdown of academic impact, for papers by Corneel Coens Breakdown of academic impact, for papers by Martine Extermann Breakdown of academic impact, for papers by Floortje Mols Breakdown of academic impact, for papers by S B Yellen Breakdown of academic impact, for papers by Theresa H.M. Keegan Breakdown of academic impact, for papers by Shabbir M.H. Alibhai
Rankless by CCL
2026